Treatment of Osteoporosis: Unmet Needs and Emerging Solutions

참고문헌 (43)

1. Johnell O, "Predictive value of BMD for hip and other fractures", J Bone Miner Res, 20, pp.1185~1194 (2005)[DOI]
2. Strom O, "Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)", Arch Osteoporos, 6, pp.59~155 (2011)[DOI]
3. Kado DM, "Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group", Arch Intern Med, 159, pp.1215~1220 (1999)[DOI]
4. Kannegaard PN, "Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival", Age Ageing, 39, pp.203~209 (2010)[DOI]
5. Eriksen EF, "Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease", Endocr Rev, 7, pp.379~408 (1986)[DOI]
6. Langdahl BL, "Medical treatment of osteoporotic vertebral fractures", Ther Adv Musculoskelet Dis, 3, pp.17~29 (2011)[DOI]
7. Langdahl B, "Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis", Ther Adv Musculoskelet Dis, 8, pp.225~235 (2016)[DOI]
8. Poole KE, "Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation", FASEB J, 19, pp.1842~1844 (2005)[DOI]
9. van Bezooijen RL, "Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist", J Exp Med, 199, pp.805~814 (2004)[DOI]
10. Padhi D, "Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody", J Bone Miner Res, 26, pp.19~26 (2011)[DOI]
11. McClung MR, "Romosozumab in postmenopausal women with low bone mineral density", N Engl J Med, 370, pp.412~420 (2014)[DOI]
12. Ferrari S, "Future directions for new medical entities in osteoporosis", Best Pract Res Clin Endocrinol Metab, 28, pp.859~870 (2014)[DOI]
13. Atkins GJ, "Osteocyte regulation of bone mineral: a little give and take", Osteoporos Int, 23, pp.2067~2079 (2012)[DOI]
14. Genant HK, "Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass", J Bone Miner Res, 32, pp.181~187 (2017)[DOI]
15. Keaveny TM, "Greater gains in spine and hip strength for romosozumab compared with teriparatide in postmenopausal women with low bone mass", J Bone Miner Res, 32, pp.1956~1962 (2017)[DOI]
16. McClung MR, "Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone nineral density: A randomized, double-blind, phase 2, parallel group study", J Bone Miner Res, 33, pp.1397~1406 (2018)[DOI]
17. Cosman F, "Romosozumab treatment in postmenopausal women with osteoporosis", N Engl J Med, 375, pp.1532~1543 (2016)[DOI]
18. Saag KG, "Romosozumab or alendronate for fracture prevention in women with osteoporosis", N Engl J Med, 377, pp.1417~1427 (2017)[DOI]
19. Langdahl BL, "Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial", Lancet, 390, pp.1585~1594 (2017)[DOI]
20. Chouinard L, "Carcinogenicity risk assessment of romosozumab: a review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study", Regul Toxicol Pharmacol, 81, pp.212~222 (2016)[DOI]
21. Juppner H, "A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide", Science, 254, pp.1024~1026 (1991)[DOI]
22. Tam CS, "Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration", Endocrinology, 110, pp.506~512 (1982)[DOI]
23. McClung MR, "Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass", Arch Intern Med, 165, pp.1762~1768 (2005)[DOI]
24. Dempster DW, "Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial", J Clin Endocrinol Metab, 97, pp.2799~2808 (2012)[DOI]
25. Hoare SR, "Measurement of agonist and antagonist ligand-binding parameters at the human parathyroid hormone type 1 receptor: evaluation of receptor states and modulation by guanine nucleotide", J Pharmacol Exp Ther, 289, pp.1323~1333 (1999)
26. Dean T, "Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH", PTHrP receptor, 2008, pp.22, 156~166
27. Culler MD, "BIM-44058, a novel analog of PTHrP with enhanced bone building activity, but decreased calcium-mobilization potential", J Bone Miner Res, 16, pp.S540~ (2001)
28. Hattersley G, "Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling", Endocrinology, 157, pp.141~149 (2016)[DOI]
29. Leder BZ, "Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis", J Clin Endocrinol Metab, 100, pp.697~706 (2015)[DOI]
30. Miller PD, "Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial", JAMA, 316, pp.722~733 (2016)[DOI]
31. Cosman F, "Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial", Mayo Clin Proc, 92, pp.200~210 (2017)[DOI]
32. Black DM, "The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis", N Engl J Med, 349, pp.1207~1215 (2003)[DOI]
33. Finkelstein JS, "The effects of parathyroid hormone, alendronate, or both in men with osteoporosis", N Engl J Med, 349, pp.1216~1226 (2003)[DOI]
34. Walker MD, "Combination therapy with risedronate and teriparatide in male osteoporosis", Endocrine, 44, pp.237~246 (2013)[DOI]
35. Gasser JA, "PTH and interactions with bisphosphonates", J Musculoskelet Neuronal Interact, 1, pp.53~56 (2000)
36. in postmenopausal osteoporosis, "J Bone Miner Res", 2011, 503~511, 10.1002[DOI]
37. Tsai JN, "Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial", Lancet, 382, pp.50~56 (2013)[DOI]
38. Kendler DL, "Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial", Lancet (2017)
39. Roux C, "Imminent fracture risk", Osteoporos Int, 28, pp.1765~1769 (2017)[DOI]
40. Johansson H, "Imminent risk of fracture after fracture", Osteoporos Int, 28, pp.775~780 (2017)[DOI]
41. Center JR, "Risk of subsequent fracture after low-trauma fracture in men and women", JAMA, 297, pp.387~394 (2007)[DOI]
42. McLellan AR, "The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture", Osteoporos Int, 14, pp.1028~1034 (2003)[DOI]
43. McLellan AR, "Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision", Osteoporos Int, 22, pp.2083~2098 (2011)[DOI]

관련 논문AI추천